# Thrombolysis in Factor Xa-inhibitors Trial

Study · id `cardio:ct-nct06878066` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06878066](<https://clinicaltrials.gov/study/NCT06878066>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06878066

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06878066. Randomized; single masking; primary purpose treatment. Start 2025-03-14 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06878066, source copy `cardio:ctgov-nct06878066-2026-11-04`, retrieved 2026-11-18)
- Started: 2025-03-14 (actual) (ClinicalTrials.gov record NCT06878066, source copy `cardio:ctgov-nct06878066-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06878066, source copy `cardio:ctgov-nct06878066-2026-11-04`, retrieved 2026-11-18)
- Completion: 2037-12-31 (anticipated) (ClinicalTrials.gov record NCT06878066, source copy `cardio:ctgov-nct06878066-2026-11-04`, retrieved 2026-11-18)
- Countries: Denmark; Norway; Sweden (ClinicalTrials.gov record NCT06878066, source copy `cardio:ctgov-nct06878066-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06878066-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: Thrombolysis in Factor Xa-inhibitors Trial
- Acronym: SIFT
- Condition: Stroke
- Condition: Stroke (in Patients With Atrial Fibrillation)
- Condition: Ischemic Stroke
- Condition: Acute Ischemic Stroke
- Condition: Anticoagulant Therapy
- Condition: Factor Xa Inhibitor
- Condition: Intracranial Hemorrhages
- Condition: Hemorrhagic Transformation Due to Acute Stroke
- Condition: Bleeding in the Brain
- Intervention (Drug): thrombolysis therapy
- Lead sponsor: Guri Hagberg
- Lead sponsor class: OTHER
- Collaborator: Klinbeforsk
- Collaborator class: OTHER
- Collaborator: Clinical Trial Unit (CTU), Oslo University Hospital
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 3247b8f6d46320992fbf5a348e462f23ede081ad00fd7f3caf1656ef49dbd89f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
